Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

СОВРЕМЕННЫЕ ПРИНЦИПЫ АНТИТРОМБОЦИТАРНОЙ ТЕРАПИИ В ЛЕЧЕНИИ БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА

https://doi.org/10.15829/1728-8800-2014-4-69-74

Полный текст:

Аннотация

Чрескожные коронарные вмешательства (ЧКВ) все шире используются как метод реваскуляризации миокарда при ишемической болезни сердца (ИБС). Двойная антитромбоцитарная терапия, включая ацетилсалициловую кислоту и клопидогрел, вошла в рутинную практику лечения пациентов с ИБС, направляемых на ЧКВ для предотвращения развития тромбоза. Максимальная оптимизация двойной антитромбоцитарной терапии с оценкой степени агрегации тромбоцитов после проведенного ЧКВ может иметь дополнительное влияние на кардиоваскулярную заболеваемость и смертность. 

Об авторах

С. Т. Мацкеплишвили
Научный центр сердечно-сосудистой хирургии им. А.Н. Бакулева РАМН, Москва
Россия
д.м.н., с.н.с. клинико-диагностического отделения


Я. Э. Арутюнова
Научный центр сердечно-сосудистой хирургии им. А.Н. Бакулева РАМН, Москва
Россия

аспирант отделения

Тел.: (499) 414–77–55 



Список литературы

1. The World Health Report 2001. Geneva: WHO; 2001.

2. Panchenko EP. The concept is the basis of the pathogenesis of atherothrombotic cardiovascular disease. Russian Medical Journal 2005; 15: 433–9. Russian (Панченко Е.П. Концепция атеротромбоза — основа патогенеза сердечно- сосудистых заболеваний. Русский медицинский журнал 2005; 15: 433–9.

3. Choi BG, Fuster V. Clinical approach to the patient whiththrombosis. In-Platelets in hematologic and cardiovascular disorders-Cambridge University Press 2008; 261–78.

4. Phillips DR, Conley PB, Sinha U, Andre P. Therapeutic approaches in arterial thrombolysis. Thrombosis Journal 2005; 8: 1577–89.

5. Baryshnikova GA. The role of clopidogrel in the treatment and prevention of cardiovascular diseases. CONSILIUM MEDICUM 2008; 11 (10): 130–7. Барышникова Г.А. Роль клопидогреля в лечении и профилактике сердечно- сосудистых заболеваний. CONSILIUM MEDICUM 2008; 11 (10): 130–7.

6. Kurlyanskaya EK, Atroschenko ES, Gevorgyan TT, Denisevich TL. Topical issues of antiplatelet therapy. Cardiology in Belarus 2008; 1 (1): 75–9. Russian (Курлянская Е.К., Атрощенко Е.С., Геворкян Т.Т., Денисевич Т.Л. Актуальные вопросы антиагрега- ционной терапии. Кардиология в Беларуси 2008; 1 (1): 75–9.

7. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179–89.

8. Steinhubl SR, Berger PB, Brennan DM, Topol EJ. Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention. JACC 2006; 47: 939–43.

9. Deepak L, Bhatt MD, Keith AA. Fox, et al. Clopidogrel and Aspirin versus Aspirin A lone fore the Prevention of Atherothrombotic Events. N Engl J Med 2006; 354: 1706–17.

10. Diener HC, Bogousslavsky J, Brass L, et al. Aspirin and clopidogrel compared with clopidogrel alone after resent ischaemic stroke or transient ischaemic attack in high￾risk patients. Lancet 2004; 364: 331–7.

11. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607–21.

12. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179–89.

13. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297 (2): 159–68.

14. Nordmann AJ, Hengstler P, Harr T, et al. Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. Am J Med 2004; 116: 253–62.

15. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115: 813–8.

16. Park D-W, Park S-W, Park K-H, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98: 352–6.

17. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109: 1930–2.

18. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events afterclopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. JACC 2006; 48: 2584–91.

19. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218–30.

20. Ra¨ber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation 2011; 123: 2819–28.

21. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393–402.

22. Van de Werf F, Bax J, Betriu A, el al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909–45.

23. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115: 813–8.

24. Wijns W, Kolh P, Danchin N, et al. The CME text ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation is accredited by the European Board for Accreditation in Cardiology (EBAC). Eur Heart J 2010; 31: 2501–55.

25. Hansen ML, Sшrensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433–41.

26. Lip GY, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary–a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010; 31: 1311–8.

27. Mehta SR, Tanguay J-F, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT￾OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233–43.

28. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–15.

29. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122: 2131–41.

30. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo controlled trial. Lancet 2005; 366: 1607–21.

31. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with Stsegment elevation. N Engl J Med 2005; 352: 1179–89.

32. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. JACC 2007; 49: 1982–8.

33. Bavry A, Kumbhani D. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006; 119: 1056–61.

34. Wiviott SD, Braunwald E, McCabe CH, et al. for the TRITON–TIMI 38 Investigators. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001–15.

35. Yavelov I.S. On the approachto the selection of antiplatelet agents for dualantiplatelet therapy for acute coronary syndrome. Clinical Pharmacology and Therapeutics 2012; 21 (3): 46–53. Russian (Явелов И.С. О подходах к выбору антиагрегантов для двойной антитромбоцитарной терапии острого коронарного синдрома. Клиническая фармакология и терапия 2012; 21 (3): 46–53).


Для цитирования:


Мацкеплишвили С.Т., Арутюнова Я.Э. СОВРЕМЕННЫЕ ПРИНЦИПЫ АНТИТРОМБОЦИТАРНОЙ ТЕРАПИИ В ЛЕЧЕНИИ БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА. Кардиоваскулярная терапия и профилактика. 2014;13(4):69-74. https://doi.org/10.15829/1728-8800-2014-4-69-74

For citation:


Matskeplishvili S.T., Arutyunova S.Y. CONTEMPORARY APPROACHES TO ANTIPLATELET THERAPY IN CORONARY HEART DISEASE TREATMENT. Cardiovascular Therapy and Prevention. 2014;13(4):69-74. (In Russ.) https://doi.org/10.15829/1728-8800-2014-4-69-74

Просмотров: 168


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)